The Latest Breaking News on Pharma

British group says claims products cause serious bowel condition NEC are ‘not supported by science’

Australia's health system could come to a "grinding halt" within days if a shortage of intravenous fluid isn't addressed, a leading doctor has warned.

The chairman and president of a major Japanese dietary supplement maker announced their resignation on Tuesday, as the company probes dozens of deaths potentially linked to products meant to lower cholesterol.

Associate Health Minister David Seymour’s recent letter of expectations to drug buying agency Pharmac could fundamentally change the way the organisation makes decisions. Some of these changes could also make Pharmac’s job harder and its decisions more unpopular.

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat…

With an aging population, increasing drug demand, and the development of advanced technologies, the healthcare industry is booming. Thus, it could be wise to invest in fundamentally sound healthcare stocks, Veeva Systems (VEEV), Align Technology (ALGN), and Medpace Holdings (MEDP), which have high-profit margins. Read on.

The pharmaceutical industry is flourishing due to increasing medical demands and rising healthcare spending worldwide. Hence, pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck & Co. (MRK), with strong pipelines, might be worth buying. Read more….

Shenzhen Component Index closed down 0.18%

OxyContin maker Purdue Pharma, the family that owns it and lawyers for thousands of parties with claims against it are getting ready to work on a new settlement after the U.S. Supreme Court rejected the last one

Medical advocacy groups welcomed Johnson & Johnson’s decision not to enforce its patent on a critical tuberculosis medication, allowing its production at much lower prices, after South African authorities opened an investigation into the conglomerate